Document:

exv10w6

Exhibit 10.6

Second Amendment to Restated Employment Agreement

     This Second Amendment to Restated Employment Agreement is made effective on the 2nd day of
August 2010, between Coeur d’Alene Mines Corporation (“Company”) and Donald J. Birak (“Employee”).

     Whereas,
the parties executed an Employment Agreement dated July 1, 2005 (the
“Employment Agreement”), and

     Whereas the Employment Agreement was further amended and then subsequently restated effective
December 31, 2008 (“Restated Employment Agreement”), and

     Whereas the Restated Employment Agreement was further amended effective July 31, 2009 whereby
the term of the Restated Employment Agreement was extended through July 31, 2011, and

     Whereas the parties desire to further extend the term of the Restated Employment Agreement and
update the compensation as contemplated by the Restated Employment Agreement and as set forth
below;

NOW THEREFORE, in consideration of the mutual promises and covenants herein contained to be kept
and performed by the parties hereto, the parties agree as follows:

1. Term Of Employment. The Restated Employment Agreement shall be amended in Section 2 to
read that the term of employment shall be extended to the 31st day of December 2011,
unless sooner terminated as provided in the Restated Employment Agreement. It is further agreed
that the Restated Employment Agreement may be further considered for additional extension. It is
understood, however, that termination can occur in accordance with the provisions of paragraph 7 of
the Restated Employment Agreement, notwithstanding anything to the contrary in this SEcond
Amendment to the Restated Employment Agreement.

2. Compensation. The Restated Employment Agreement shall be amended in Section 3 (a) to
read that the Employee shall receive a base salary of $282,000 annually. The Restated Employment
Agreement shall be amended in Section 3 (c) to read that the Employee shall have an opportunity to
earn a bonus during each calendar year targeted to be 50% of Employee’s then current annual salary,
which, at the date of this Agreement, is the potential sum of $141,000 and a maximum of $282,000
(AIP). In

 

 

addition, Employee shall be eligible to earn an award under the Company’s long-term incentive plan
with a target level of 190% or a potential $535,800 (LTIP). Such bonuses are at the discretion of
the board of directors.

IN WITNESS WHEREOF, the parties have executed this Second Amendment to the Restated Employment
Agreement as of the day and year first written above.

Coeur d’Alene Mines Corporation

	 	 	 	 
	By  	/s/ Dennis E. Wheeler	 
	Dennis E. Wheeler, President and CEO 	 
	 
	/s/ Donald J. Birak
 	 
	Employeeexv10w7

Exhibit 10.7

Second Amendment to Restated Employment Agreement

     This Second Amendment to Restated Employment Agreement is made effective on the 2nd day of
August 2010, between Coeur d’Alene Mines Corporation (“Company”) and Kelli C. Kast (“Employee”).

     Whereas,
the parties executed an Employment Agreement dated June 1, 2005 (the
“Employment Agreement”), and

     Whereas the Employment Agreement was further amended and then subsequently restated effective
December 31, 2008 (“Restated Employment Agreement”), and

     Whereas the Restated Employment Agreement was further amended effective July 31, 2009 whereby
the term of the Restated Employment Agreement was extended through July 31, 2011, and

     Whereas the parties desire to further extend the term of the Restated Employment Agreement and
update employment and compensation as contemplated by the Restated Employment Agreement and as set
forth below;

NOW THEREFORE, in consideration of the mutual promises and covenants herein contained to be kept
and performed by the parties hereto, the parties agree as follows:

1. Employment. The Restated Employment Agreement shall be amended in Section 1 to read
that the Company agrees to, and hereby does, employ Employee as Senior Vice President, General
Counsel, Chief Administrative Officer and Corporate Secretary.

2. Term Of Employment. The Restated Employment Agreement shall be amended in Section 2 to
read that the term of employment shall be extended to the 31st day of December 2011,
unless sooner terminated as provided in the Restated Employment Agreement. It is further agreed
that the Restated Employment Agreement may be further considered for additional extension. It is
understood, however, that termination can occur in accordance with the provisions of paragraph 7 of
the Restated Employment Agreement, notwithstanding anything to the contrary in this Second
Amendment to the Restated Employment Agreement.

3. Compensation. The Restated Employment Agreement shall be amended in Section 3 (a) to
read that the Employee shall receive a base salary of $289,000 annually. The Restated Employment

 

 

Agreement shall be amended in Section 3 (c) to read that the Employee shall have an opportunity to
earn a bonus during each calendar year targeted to be 50% of Employee’s then current annual salary,
which, at the date of this Agreement, is the potential sum of $144,500 and a maximum of $289,000
(AIP). In addition, Employee shall be eligible to earn an award under the Company’s long-term
incentive plan with a target level of 190% or a potential $549,100 (LTIP). Such bonuses are at the
discretion of the board of directors.

4. Residency and Work Location. Employee resides in the State of Colorado and works
primarily from her home office on a telecommuting basis. As such, employee shall be available by
remote access at all times, and as required to execute her employment duties. Employee shall,
however, commute to the corporate offices in Coeur d’Alene on a bi-weekly basis, for a minimum of
three days, or to such other locations as may be necessary to carry out her employment
responsibilities. The Company shall pay the transportation costs of Employees’ airline travel to
commute on this basis, with other commuting expenses the responsibility of the Employee.

IN WITNESS WHEREOF, the parties have executed this Second Amendment to the Restated Employment
Agreement as of the day and year first written above.

Coeur d’Alene Mines Corporation

	 	 	 	 
	By  	/s/ Dennis E. Wheeler	 
	Dennis E. Wheeler, President and CEO 	 
	 
	/s/ Kelli C. Kast
 	 
	Employeeexv10w8

Exhibit 10.8

Third Amendment to Restated Employment Agreement

     This Third Amendment to Restated Employment Agreement is made effective on the 2nd day of
August 2010, between Coeur d’Alene Mines Corporation (“Company”) and K. Leon Hardy (“Employee”).

     Whereas,
the parties executed an Employment Agreement dated July 1, 2008 (the
“Employment Agreement”), and

     Whereas the Employment Agreement was further amended and then subsequently restated effective
December 31, 2008 (“Restated Employment Agreement”), and

     Whereas the Restated Employment Agreement was further amended effective July 31, 2009 whereby
the term of the Restated Employment Agreement was extended through July 31, 2011, and

     Whereas the Restated Employment Agreement was further amended on March 2, 2010 whereby the
employment, compensation and duties were addressed, and

     Whereas the parties desire to further extend the term of the Restated Employment Agreement as
contemplated by the Restated Employment Agreement and as set forth below;

NOW THEREFORE, in consideration of the mutual promises and covenants herein contained to be kept
and performed by the parties hereto, the parties agree as follows:

1. Term Of Employment. The Restated Employment Agreement shall be amended in Section 2 to
read that the term of employment shall be extended to the 31st day of December 2011,
unless sooner terminated as provided in the Restated Employment Agreement. It is further agreed
that the Restated Employment Agreement may be further considered for additional extension. It is
understood, however, that termination can occur in accordance with the provisions of paragraph 7 of
the Restated Employment Agreement, notwithstanding anything to the contrary in this Third Amendment
to the Restated Employment Agreement.

 

 

IN WITNESS WHEREOF, the parties have executed this Third Amendment to the Restated Employment
Agreement as of the day and year first written above.

Coeur d’Alene Mines Corporation

	 	 	 	 
	By  	/s/ Dennis E. Wheeler	 
	Dennis E. Wheeler, President and CEO 	 
	 
	/s/ K. Leon Hardy
 	 
	Employeeexv10w1

Exhibit 10.1

AMENDMENT NO. 4

relating to that certain

SPONSORED RESEARCH AND LICENSE AGREEMENT

between

CORNERSTONE THERAPEUTICS INC., FORMERLY KNOWN AS CRITICAL

THERAPEUTICS, INC.,

and

THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH

dated as of

JANUARY 1, 2003

THIS AMENDMENT NO. 4 is made the 3rd day of August, 2010

BETWEEN:

	(1)	 	Cornerstone Therapeutics Inc., formerly known as Critical Therapeutics, Inc., a Delaware
corporation (“CTI”); and
	 
	(2)	 	The Feinstein Institute for Medical Research, a New York not-for-profit corporation
(“Feinstein”)

RECITALS:

	 	(A)	 	CTI and Feinstein entered into a Sponsored Research and License Agreement, dated
January 1, 2003.
	 
	 	(B)	 	The said Sponsored Research and License Agreement was modified by that certain Letter
Agreement between CTI and Feinstein dated February 3, 2004, and was amended by each of
Amendment No. 1 dated September 18, 2006, Amendment No. 2 dated January 8, 2007 and
Amendment No. 3 dated June 29, 2007 and that certain Letter Agreement effective September
26, 2007. The Sponsored Research and License Agreement as so modified and so amended is
referred to herein as the “Original Agreement”.
	 
	 	(C)	 	In November 2008, Cornerstone BioPharma Holdings merged with Critical Therapeutics,
Inc. and Critical Therapeutics, Inc. changed its name to Cornerstone Therapeutics Inc.
	 
	 	(D)	 	CTI and Feinstein have agreed to amend the Original Agreement by and upon the terms
of this Amendment No. 4.

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

1

 

OPERATIVE PROVISIONS:

1. Introduction, Definitions and Interpretation

	1.1.	 	This Amendment No. 4 is supplemental to the Original Agreement.
	 
	1.2.	 	In this Amendment No. 4, the expression “this Amendment No. 4” shall mean this Amendment No.
4, including its recitals and schedules.
	 
	1.3.	 	Except where expressly provided to the contrary in this Amendment No. 4:

	 	1.3.1	 	all capitalized terms used in this Amendment No. 4 shall have the same
meanings as are assigned thereto in the Original Agreement, as amended by this
Amendment No. 4; and
	 
	 	1.3.2	 	this Amendment No. 4 shall be interpreted in the same manner as the Original
Agreement.

	1.4.	 	References to clauses and Articles herein are to clauses and Articles of the Original
Agreement.

2. Amendments

NOW THEREFORE, in consideration of the mutual covenants contained in the Original Agreement and in
this Amendment No. 4 and other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties agree that with effect from the Amendment No. 4 Date (as
defined below), the Original Agreement is hereby amended as follows:

2.1.
Article 1 shall be amended by insertion of the following additional definition after Article 1.2(d).:

     “1.2(e). “Amendment No. 4 Date” shall mean August 3rd, 2010.”

2.2. The parties acknowledge and agree that Cornerstone Therapeutics Inc. has succeeded to Critical
Therapeutics, Inc.’s interest in the Original Agreement, that all references to Critical
Therapeutics, Inc. or CTI in the Original Agreement are references to Cornerstone Therapeutics Inc.
and that Cornerstone Therapeutics Inc. is required to satisfy the obligations of Critical
Therapeutics, Inc. set forth in the Original Agreement.

2.3. The parties acknowledge and agree that the Research Term has expired.

2.4. The parties acknowledge and agree that prior to the Amendment No. 4 Date, CTI returned certain
Feinstein Patent Rights to Feinstein pursuant to Section 5.4 of the

2

 

Original Agreement and made certain changes to the Field of the Original Agreement. By this Amendment No. 4, CTI and Feinstein
negate and nullify the prior return of any and all Feinstein Patent Rights and also negate and
nullify any and all prior changes to the Field. An amended, updated and restated Schedule 1.7,
including all patent applications and patents included in the definition of Feinstein Patent Rights
as of the Amendment No. 4 Date is attached hereto as Exhibit A and is incorporated herein. The
Schedule 1.7 attached hereto as Exhibit A supersedes and replaces all prior versions of Schedule
1.7.

2.5. The parties acknowledge and agree that the following patent applications (which are included
in Schedule 1.7) and all patent rights claiming priority (directly or indirectly) thereto are
jointly owned by Feinstein and SetPoint Medical Corporation (formerly Innovative Metabolics, Inc.),
a Delaware corporation (“SetPoint”): U.S. Patent Application No. [***] and PCT Patent Application
No. [***], “[***]”, and U.S. Patent Application No. [***] and PCT Patent Application No. [***],
“[***]”. CTI acknowledges and agrees that there is no agreement between SetPoint and CTI regarding
these jointly owned patent rights and that all rights granted by Feinstein to CTI for these jointly
owned patent rights are subject to and limited by SetPoint’s rights under 35 U.S.C. Section 262.

2.6. The parties acknowledge and agree that the following patent applications (which are included
in Schedule 1.7) and all patent rights claiming priority (directly or indirectly) thereto are
jointly owned by Feinstein and a third party (presumably [***]): U.S. Patent Application No. [***]
and PCT Patent Application No. [***], “[***]”. CTI acknowledges and agrees that there is no
agreement between the third party and CTI regarding these jointly owned patent rights and that all
rights granted by Feinstein to CTI for these jointly owned patent rights are subject to and limited
by the third party’s rights under 35 U.S.C. Section 262.

2.7. CTI hereby acknowledges and agrees that the following patent applications (which are not
included in Schedule 1.7) and all patent rights claiming priority (directly or indirectly) thereto
are owned solely by SetPoint: U.S. Provisional Patent Application No. [***] and U.S. Utility
Patent Application No. [***], “[***]”, and U.S. Provisional Patent Application Nos. [***] and [***]
and PCT Patent Application No. [***], “[***]”.

2.8 With respect to those Feinstein Patent Rights previously returned to Feinstein by CTI and
referenced above in paragraph 2.4 of this Amendment No. 4, CTI acknowledges its obligation
consistent with Article 5.2 of the Original Agreement to reimburse Feinstein for all of the patent
prosecution costs incurred by Feinstein following such return. In full settlement of such
obligation, upon execution of this Amendment No. 4, CTI shall pay to Feinstein the amount of [***]
Dollars ($[***]).

3. No Other Amendments; Confirmation

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately
with the Securities and Exchange Commission.

3

 

Save as amended by this Amendment No. 4, the parties hereto confirm that the Original
Agreement shall continue in full force and effect in all respects.

4. Counterparts

This Amendment No. 4 may be signed in any number of counterparts with the same effect as if the
signatures to each counterpart were upon a single instrument, and all such counterparts together
shall be deemed an original of this Amendment No. 4.

5. Governing Law and Jurisdiction

This Amendment No. 4 shall be governed by and construed in accordance with the laws of the State of
New York without regard to any conflict of laws provisions thereof.

IN WITNESS whereof the parties have executed and delivered this Amendment No. 4 as of the Amendment
No. 4 Date.

	 	 	 	 	 
	CTI

Cornerstone Therapeutics Inc.

 	 	 
	By:  	/s/ Andrew Powell
 	 	 
	 	Name:  	Andrew Powell 	 	 
	 	Title:  	Secretary 	 	 
	 
	Feinstein

The Feinstein Institute For Medical Research

 	 	 
	By:  	/s/ Kirk R. Manogue, PhD
 	 	 
	 	Name:  	Kirk R. Manogue, PhD 	 	 
	 	Title:  	Vice President, Technology Transfer 	 	 

4

 

	 	 	 	 	 

EXHIBIT A to AMENDMENT No. 4

SCHEDULE 1.7

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	CRTX	 	Attorney	 	 	 	 	 	 	Application number,	 	 	 	 	 	 	 
	Docket	 	Docket	 	 	 	 	 	 	filing date and	 	 	 	 	 	 	 
	Number	 	Number	 	 	Application Title	 	 	priority	 	 	Inventor(s)	 	 	Status	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

5

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	CRTX	 	Attorney	 	 	 	 	 	 	Application number,	 	 	 	 	 	 	 
	Docket	 	Docket	 	 	 	 	 	 	filing date and	 	 	 	 	 	 	 
	Number	 	Number	 	 	Application Title	 	 	priority	 	 	Inventor(s)	 	 	Status	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

6

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	CRTX	 	Attorney	 	 	 	 	 	 	Application number,	 	 	 	 	 	 	 
	Docket	 	Docket	 	 	 	 	 	 	filing date and	 	 	 	 	 	 	 
	Number	 	Number	 	 	Application Title	 	 	priority	 	 	Inventor(s)	 	 	Status	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

7

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	CRTX	 	Attorney	 	 	 	 	 	 	Application number,	 	 	 	 	 	 	 
	Docket	 	Docket	 	 	 	 	 	 	filing date and	 	 	 	 	 	 	 
	Number	 	Number	 	 	Application Title	 	 	priority	 	 	Inventor(s)	 	 	Status	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

8

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	CRTX	 	Attorney	 	 	 	 	 	 	Application number,	 	 	 	 	 	 	 
	Docket	 	Docket	 	 	 	 	 	 	filing date and	 	 	 	 	 	 	 
	Number	 	Number	 	 	Application Title	 	 	priority	 	 	Inventor(s)	 	 	Status	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(end)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]